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The stoichiometry of the subunits that comprise the T  cell antigen receptor (TCR) complex 
is not completely known. In particular, it is uncertain whether TCR ot and TCR/5 proteins 
are present in the TCR complex as one or multiple heterodimeric pairs.  In this study we have 
used mice transgenic for two different TCR ot and two different TCR/5 proteins to determine 
the number of TCR a  and TCR/5 chains in a single TCR complex. Individual thymocytes 
and splenic T cells from double TCR transgenic mice simultaneously expressed all four transgenic 
TCR proteins on their surfaces. Because the individual TCR ot and individual TCR/5 proteins 
were biochemically distinguishable, we were able to examine associations  among the transgenic 
TCR products. We found that each TCR ct chain paired with each TCR/5 chain, but that 
each TCR complex contained only one TCR ot and one TCR B protein. Furthermore, quantitative 
immunofluorescence revealed that T  cells expressed  twice as many CD3e as TCR/5 proteins. 
These findings demonstrate that there are precisely  one TCR a, one TCR/5, and two CD3e 
chains in each TCR/CD3 complex expressed on the surfaces of  both thymocytes and mature T cells. 
T 
he TCR, a heterodimer of ot and/5 proteins,  is expressed 
on the surface oft lymphocytes as part ofa multisubunit 
complex that includes the CD3 proteins (CD33,, tS, and e) 
and a dimer of the ~'protein family (1). Although all members 
of the surface TCR/CD3 complex have been identified, their 
stoichiometry has not yet been completely determined. Re- 
cent studies showing that at least two, and possibly only two, 
CD3e proteins are present per TCR/CD3 complex have led 
to a reevaluation of TCR/CD3 structure and the proposal 
that CD3 components exist in a single complex as two dimers 
of 3'/e and ~/~ proteins (2-4). Several groups have also raised 
the possibility that there are two TCR a  and two TCR 
chains in a single TCR complex (5,  6),  arguing that such 
an arrangement would facilitate signal transduction after TCR 
engagement by antigen and would result in an electrostati- 
cally neutral and, hence, more stable  protein complex. 
To determine whether there were more than one TCR ot 
or TCR/3 protein in a single TCR/CD3 complex, we exam- 
ined associations  among components of surface  TCR  on 
thymocytes and splenic T cells coexpressing two different TCR 
ot and two different TCR ~ chains. The results of these ex- 
periments provide a unique solution to the stoichiometry of 
the TCR/CD3 complex and demonstrate that there are only 
one TCR ot chain, one TCR ~ chain, and two CD3 e chains 
in a single TCR/CD3 complex. 
Materials  and Methods 
Mice.  Mice transgenic for the AND TCR ot and/~ chains (7) 
were originally provided by S. Hedrick (University of California 
at San Diego, La Jolla, CA) and were bred in our facility. They 
had been backcrossed  for more than 10 generations  onto a C57BL/6- 
LyS.2 background. Mice transgenic for the anti-H-Y TCR a  and 
/~ chains (8) were originally provided by H. von Boehmer (Basel 
Institute, Basel, Switzerland) and were bred in our facility.  Double 
transgenic mice were generated by crossing a mouse heterozygous 
for the AND transgenes with a mouse heterozygous for the anti- 
H-Y transgenes. Progeny were screened  for the expression  of trans- 
genic TCR products by examining PBL for surface expression of 
the AND TCR ct (ANDVc~11) and the anti-H-Y TCR/3 ("-vVa8) 
chains. Female  single and double TCR transgenic animals  were used 
in these studies. 
Antibodies.  Biotinylated  mAbs anti-V~11 (RR8-1 [9]) and anti- 
Va3 (KJ-25 [10]) are specific for the AND TCR cr  and TCR/~ 
chains, respectively,  were purchased from PharMingen (San Diego, 
CA). T3.70, the mAb specific  for the anti-H-Y TCR ot chain V~3, 
was provided by H. von Boehmer (8) and conjugated to FITC in 
our lab. mAb anti-Va8.1, 8.2, 8.3 (F23.1 [11]) binds the anti-H-Y 
TCR ~ chain and was purified and conjugated to FITC in our lab. 
mAb anti-CD3e (145-2Cll [12]) was used as a hybridoma super- 
natant for precipitations and as a protein A-purified preparation 
for quantitative  surface  staining.  Both mAb anti-CD3e (500A2 [13]) 
and mAb anti-TCR B (H57-597 [14]) were also used as protein 
A-purified preparations for quantitative surface staining. 
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Single cell suspensions of thymocytes were prepared by gently teasing 
cells from the thymic capsule and filtering over nylon mesh. Splenic 
T ceils were prepared by panning murine splenocytes  on plates coated 
with rabbit anti-mouse Ig (Organon  Teknika, Durham, NC) to 
rid  the population  of B cells and adherent  ceils. Splenic CD4 + 
(CDS-depleted) T cells were prepared from C57BL/6 mice by fur- 
ther treating  the cells with anti-CD8  (3.155 [15]), anti-NKl.1 
(PK136 [16]), anti-I-A  b'd,q (M5/114.15.2 [17]) and rabbit comple- 
ment for 30 min at 370C, and then with rabbit complement alone 
for another 30 rain at 37~  Viable cells were collected after cen- 
trifugation  over Lympholyte-M  (Cedarlane  Laboratories,  Ltd., 
Hornby,  Canada). 
Staining.  Murine  thymocytes  and splenic T  calls (5  x  l0  s) 
were stained with saturating  concentrations  of biotinylated  and 
FITC-conjugated  reagents in 40 #1 for 30 min at 40C, washed in 
200 #1 staining medium  (HBSS, 0.1%  BSA, 0.1%  NAN3) three 
times, then stained in 40 #1 with saturating concentrations of Texas 
Red streptavidin for 15 min at 40C. Cells were washed again and 
analyzed on a FACStar Plus  |  (Becton Dickinson & Co., Mountain 
View, CA). For quantitative immunofluorescence of splenic T cells, 
106 cells were washed and incubated at 40C for 1 h with unla- 
beled anti-TCK fl (H57-597), unlabeled anti-CD3e  (145-2Cll  or 
500A2) at concentrations determined empirically to be saturating 
(0.5 #g/ml for H57-597, 0.25 #g/ml for 145-2Cll, and 1.0 #g/ml 
for 500A2). Because these antibodies share the same isotype (ham- 
ster IgG),  their  relative binding  intensities  could be compared 
directly. After extensive washing, bound antibodies were visual- 
ized with FITC-conjugated goat anti-hamster antibody, which was 
also used at saturating  concentrations. 
Surface Ioaination, Immunoprecipitation, and  Endoglycosidase-F 
(Endoy F Digestion.  Cells were pelleted, washed with cold PBS 
and treated with Bolton Hunter reagent (18) before they were sur- 
face iodinated as described previously (19). Surface iodinated cells 
were lysed in 1% digitonin as described previously (19) and immu- 
noprecipitated with beads preadsorbed to fetal calf serum, then with 
beads preadsorbed to 2-4 #g purified antibody (anti-V~11, anti- 
Va3) or 1 ml hybridoma  supematant  (F23.1, T3.70,  and 2Cll). 
Immunoprecipitates  were  washed  in  buffer  containing  0.2% 
digitonin  (18) and digested  overnight  with Endo  F/Peptide-N- 
Glycosidase F (Endo F/PNGase F) (Oxford Glycosystems, Rose- 
dale, NY) at 37~  as per the manufacturer's  instructions. 
Two-dimensional  NEPHGE/SDS-PAGE Electrophoresis.  Immu- 
noprecipitated samples were equih'brated in 150 #1 sample buffer 
(9.5 M urea,  2% Triton X-100, 1.6% Ampholyte 5-7 [Bio-Rad 
Laboratories, Richmond, CA], 0.4%  Ampholyte  3-10 [Bio-Rad 
Laboratories], 5% 2-mercaptoethanol)  and separated in tube gds 
across a pH gradient (nonequilibrium pH gradient electrophoresis 
[NEPHGE]) for 2500 volt-hours as described previously (18, 20). 
Tube gels were extruded, equilibrated at 37~  in SDS-PAGE sample 
buffer containing 2-mercaptoethanol and run in the second dimen- 
sion on a 13% reducing  PAGE gel. Gels were run for 865 Vh, 
fixed, dried,  and visualized by phosphorimagery. 
Results 
Experimental Design.  The stoichiometry of the TCR/CD3 
complex has not yet been solved and a number of TCR/CD3 
configurations are consistent with current data (Fig. 1). Vat- 
1 Abbreviations used in this pa~r: Endo F, Endoglycosidase  F; NEPHGE, 
nonequilibrium pH  gradient dectrophoresis; PNGase F,  Peptide-N- 
Glycosidase F. 
One TCR heterodimer 
TCRc~I3: CD3e = 1:2 
B  Two TCR heterodimers 
TCRc~I3: CD3e =  1:2 
Figure  1. 
C  Two TCR heterodimers 
TCRetI~: CD3e = 1:1 
Three models of TCK/CD3  stoichiometry. 
ious solutions differ by the number of TCK c~ and B chains 
present per complex and the ratio between the moles of TCK 
fl (or TCR c~) and CD3 e represented in each complex. Models 
proposing more than  one TCR ot and TCK/~  in a single 
complex predict that, on a cell expressing two different TCR 
ot chains, antibodies specific for one TCR c~ would coprecipi- 
tate the other TCR a.  Similarly,  on cells  expressing two 
different TCK/3 chains,  antibodies specific for one TCK/3 
would coprecipitate the other TCR/3 chain.  In the present 
study, we have tested this prediction by generating cells that 
coexpressed two different TCK ot and two different/3 chains 
on their surfaces and have examined associations among com- 
plex components. The usefulness of such an approach, how- 
ever, required that the two different TCR ot and two different 
TCK/3 proteins be biochemically distinguishable. 
The AND  TCR oe and TCR ~  Chains Are Biochemically 
Distinguishable  from the H-Y TCR ce and TCR ~ Chains.  We 
compared the biochemical signatures of the TCR ot and/3 
proteins expressed by mice transgenic for the AND TCK or~~3 
(Y)  with  the  biochemical  signatures  of the  TCK  c~  and 
/3 chains expressed by mice transgenic for the receptor specific 
for the male antigen H-Y (8) (hitherto referred to as the H-Y 
TCR ot/fl receptor).  Neither the AND and H-Y TCK ot 
chains (^NDV~ll  and H-W~3) nor the AND and H-Y TCR 
/3 chains  (^NDVa3 and a-YVa8 )  could be distinguished  by 
molecular weight or charge (data not shown). However, when 
stripped of their carbohydrate side chains with Endo F/PNGase 
F, which hydrolyze N-linked sugar residues, and then sepa- 
rated by charge, the two ot chains and the two/3 chains ex- 
hibited unique migration  patterns  when resolved by two- 
dimensional NEPHGE under reducing conditions (Fig.  2). 
The ^NDV~ll chain migrated as two spots, designated all1 
and  cd12  (Fig.  2)  and  the  H-vV~3  chain  migrated  as  a 
significantly  more  acidic  single  spot,  designated  ~3.  The 
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cx chains  and the AND and H-Y TCR. fl chains 
are biochemicaUy distinguishable via two dimen- 
sional NEPHGE/SDS-PAGE  anal)sis. Thymocytes 
from AND transgenic and H-Y transgenic mice 
were surface-labeled with lz5I, 1)sed in digitonin, 
and precipitated with mAbs indicated. Precipitates 
were  digested' with  Endo  F,  then  resolved  by 
NEPHGE followed by SDS-PAGE under reducing 
conditions, as indicated. Where indicated, precipi- 
tates from AND and H-Y 1)sates were mixed  just 
before  electrophoresis.  Separated  proteins were 
visualized by phosphorimagery. 
ANDV/~3  chain migrated as two major spots, designated/33t 
and fl32, as did the "-YV~8 chain,  designated/38t  and/382. 
The/382  spot  generated by H-vVa8 was significantly lower 
in molecular weight than any spot  generated  by ^NDVa3. 
Most importantly, the two TCR o~ and the two TCR/3 
chains were distinguishable from each other when anti-TCR 
ol or anti-TCR/3 precipitations from AND and H-Y thymo- 
cytes were mixed together before NEPHGE analysis. In par- 
ticular,  the appearance of the c~3 and/382  spots, unique to 
H-YV~3 and H-vVo8, respectively, provided unambiguous evi- 
dence for the presence of the H-Y transgene products in im- 
munoprecipitated preparations  (Fig. 2). 
AND/H-Y Double TCR Transgenic Thymocytes  and Spleno- 
cytes Coexpress  AND and H-Y TCR ~  and TCR ~  Proteins 
on Their Surfaces.  Because the AND and H-Y receptor pro- 
teins could be distinguished biochemically, we generated T 
cells that coexpressed both receptors by crossing mice trans- 
genic for the AND TCR odB receptor with mice transgenic 
for the H-Y TCR ex/B. Immature and mature T lympho- 
cytes in double TCR transgenic progeny expressed all four 
transgenic TCR chains (*NDVall, H-W~3 [T3.70],  ANDV~3, 
and H-YVa8  ) on their surfaces simultaneously  (Fig. 3). Sur- 
face staining revealed that the large majority of thymocytes 
in double transgenic mice bound antibodies to both ^NDVa3 
and H-YV/~8 as well as both ^NDVa11 and H-YVa3  (Fig. 3, 
bottom left). 
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Thymus  Spleen 
c 
i  o 
H-Y  == 
AND/H-Y 
ND 
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Figure  3.  Thymocytes  and  splenocytes  from 
double TCR transgenic mice coexpress both TCR 
o~ and TCR/3 chains on their surfaces. Single cell 
suspensions of thymocytes and splenic T cells from 
single and double TCR transgenic littermates were 
stained simultaneously with biotinyhted antibodies 
specific for V~11 and fluorescein-conjugated  anti- 
bodies specific for H-vV~3 (T3.70)  or with bi- 
otinylated  antibodies  specific  for  ANDV~3 and 
fluorescein  conjugated  antibodies  specific  for 
H-vV08. Cells were washed, incubated with Texas 
RM streptavidin, and analyzed on a FACStar Plus  | 
Quadrants define the boundaries of negative con- 
trol profiles. 
589  Punt  et al. Figure  4.  There is one TCR c~ and one TCR ~ chain per TCR/CD3 
complex. Thymocytes from single and double TCR transgenic mice were 
surface  labeled  with  12sI, precipitated  with  the  indicated  mAbs,  and 
digested with Endo F/PNGase as described under Materials and Methods. 
Results  are  presented  as  described  in  Fig.  2.  (A)  ANDV~11 does  not 
coprecipitate H-YVa3 and ANDVB3  does not coprecipitate H-YVB8  from the 
surface of double TCR transgenic thymocytes.  The arrows in the bottom 
left corners indicate where the or3 spot migrates (right) or where it would 
appear if H-YV,~3 were present in the anti-ANDV~,11 precipitate (left). The 
arrows in the bottom right corners  indicate  either where the B82 spot 
migrates (right)  or where it would migrate if H-YVa8 were present in the 
anti-ANDV~3 precipitate (center).  Spots that are not labeled are minor spe- 
cies whose appearance is dependent  on the extent of the exposure of the 
gels.  (B) ANDVc~ll does  not  coprecipitate  H-YV~3 from  the  surface of 
double  TCR transgenic  splenic T  cells. The arrow  indicates where the 
c~3 spot would appear if H-YV~,3  were present in the anti-ANDV,~11 precipi- 
tate.  The spleen T  cells were isolated from the same mice from which 
the thymocytes  were isolated  for the studies  shown in A. 
Immunoprecipitations supported the indication that AND 
and H-Y TCR proteins were expressed on the surface of the 
same  cells. Antibodies  to  ANDV,,11 coprecipitated  both 
ANDVa3 and H-YV~8, as shown by the appearance of the ~31, 
~32, and the spot unique to H-Y,  B82 (Fig.  4  A,  left, see 
arrow to the right).  Reciprocally, ANDV~3 coprecipitated both 
ANDV~11 and H-YV~,3 from double TCR transgenic thymo- 
cytes, as indicated by the presence of the ot111, c~112, and the 
spot unique to H-Y,  or3 (Fig. 4 A,  middle,  see arrow on the 
left). Hence, TCR ot and TCR B chains of different trans- 
genic origins shared the same receptor complex, indicating 
(a) that they were expressed on the surface of the same cell 
and (b) that the two transgenic TCP,, ot chains could freely 
associate with each of the two transgenic TCR ~  chains. 
Thymocytes  and Splenic  T  Cells Express  Only One TCR  ce 
and one TCR ~ per TCR/CD3 Complex.  As expected, anti- 
CD3e  (2Cll)  coprecipitated both  ANDVa3 and  ANDV~11 
from single AND transgenic thymocytes and precipitated both 
"-YV~8 and "-YV,,3 from single H-Y transgenic thymocytes. 
Anti-CD3E also coprecipitated all transgenic TCR chains from 
the surface of AND/H-Y double transgenic thymocytes as 
indicated by the presence of ~81 and B82 spots and by the 
presence of o~111, ol112, and c~3 spots (Fig.  4 A,  right). 
Although the AND TCR B and the H-Y TCR ~ chains 
associated with both transgenic TCR c~ chains  and with 
CD3e, they never associated with each other. Antibodies to 
ANDV,~11 failed to coprecipitate  H-YV~3 from the surface of 
double  transgenic  thymocytes,  for  the  spot  unique  to 
H-YV,~3, i.e., c~3, was absent after  NEPHGE analysis (Fig. 
4  A,  left, left  arrow) Anti-H-vv~3  (T3.70)  also  failed  to 
precipitate spots unique to ANDV~ll (data not shown). Simi- 
larly, the two transgenic TCR/~ chains did not associate with 
each  other,  for  anti-ANnV~3 failed  to  precipitate the  spot 
unique to "-YV~8, i.e., ~82 (Fig.  4 A,  middle,  right arrow). 
Thus, these data indicated that ANDVall and H-YVa3 were 
both expressed on the surface of double transgenic thymo- 
cytes but were not present in the same complex. Likewise, 
both  ANDV~3  and H-YV~8 were present on  the  surface of 
double TCR transgenic thymocytes, but were not present 
in the same complex. Therefore, each TCR complex expressed 
by double TCK transgenic thymocytes contained only one 
TCK o~ and one TCR fl chain. 
To address the possibility that stoichiometry of TCR com- 
plexes differed between immature and mature T cells, we ex- 
amined the associations of transgenic TCR ex chains expressed 
by splenic T  cells from single (AND) and double (AND/ 
H-Y)  transgenic mice (Fig.  4  B).  Anti-V~11  precipitated 
ANDv~11 from the surfaces of both AND single transgenic 
and AND/H-Y double transgenic splenic T lysates, as shown 
by the appearance of spots ot111 and ex112. However,  anti- 
V~11 did not coprecipitate H-YV~3, for the or3 spot was ab- 
sent by NEPHGE analysis. As was observed in thymocytes, 
these findings demonstrate that ANDVall was not present in 
the same TCR complex that contained H-YV~3. We con- 
clude that there is only one TCK cx per complex expressed 
by mature T  cells. 
The TCR/CD3  Complex Contains One TCR or, One TCR 
~,  and Two CD3e  Proteins.  Our findings rule out models 
of TCR/CD3 stoichiometry that propose more than one TCR 
ot and one TCR ~ chain per complex (Fig. 1, B and C) and 
also predict that CD3e chains outnumber TCR ~ chains on 
the surface of T cells (Fig. 1 A). To quantify the relative ex- 
pression levels of CD3e and TCR B proteins on normal T cells, 
we compared the densities of TCR B and CD3e on normal 
splenic T cells by immunofluorescence. When incubated with 
saturating concentrations of anti-TCR. B (H57-597)  or with 
saturating concentrations of two different anti-CD3E anti- 
bodies (either 145-2Cll or 500A2),  all of which share the 
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Figure  5.  There is a 1:2 ratio of binding sites for anti-TCR B and anti- 
CD3e on the surface of T  cells. Splenic CD4 + T  cells were prepared and 
stained for quantitative immunofluorescence as described under Materials 
and Methods. Total fluorescent units (FU)  x  10 -4 are displayed for each 
curve in parantheses.  FU  =  cell frequency  x  median intensity and me- 
dian intensity is derived by converting median logarithmic channel numbers 
to linear units via a calibration curve empirically derived for each loga- 
rithmic amplifier used. Negative control antibody fluorescence (lightly shaded) 
is subtracted. 
same isotype (hamster IgG) and subsequently incubated with 
the  same  fluorescently tagged  secondary antibody  (goat 
anti-hamster IgG), splenic T  cells stained with anti-CD3e 
fluoresced with greater intensity than those stained with anti- 
TCR/3 (Fig.  5). When total fluorescence units were com- 
pared, precisely twice as much anti-CD3e bound the surface 
of splenic T cells as anti-TCR/3, indicating that CD3e and 
TCR/3 were present at a 2:1 ratio on the T  cell surface. 
Discussion 
In the present study we assessed the stoichiometry of the 
TCR ot and TCR fl chains in the TCR/CD3 complex ex- 
pressed on the surface of immature and mature T cells. When 
associations between different TCR ex and different TCR/3 
chains of T lymphocytes from mice transgenic for two different 
TCR cx//3 heterodimers were examined, it was dear that each 
of the transgenic TCR c~ proteins freely associated with each 
transgenic TCR/3 protein, and vice versa. However, no more 
than one TCR ot and TCR/3 was ever detected in a single 
TCR complex. Antibodies specific for one transgenic TCR 
ot chain never coprecipitated the other transgenic TCR ot chain 
and, reciprocally, antibodies against one transgenic TCR/3 
chain never coprecipitated the other transgenic TCR/3 chain. 
The absence of any association between either the transgenic 
TCR oe protein or the transgenic TCR/3 chains directly rules 
out the existence of TCR complexes containing multiple in- 
dependent TCR cx//3 pairs. The present data even rule out 
models that postulate TCR complexes containing multiple 
TCR ee//3 pairs where different individual TCR. ot or different 
individual TCR/3 chains are constrained from sharing the 
same complex. For example, even if the two transgenic TCR 
r  proteins ("-vV~3  and ^NDV,dl)  were constrained from 
sharing a single complex, each anti-Vt~ antibody would have 
coprecipitated the other transgenic TCR 3  protein because 
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each transgenic TCR ot chain paired freely with both trans- 
genic TCR/3 chains. Similarly, if the two transgenic TCR 
/3 proteins ("-eVa8 and ^NDVa3) were incompatible, each 
anti-V~ antibody would have coprecipitated the other trans- 
genic TCR c~ protein because each transgenic TCR/3 chain 
paired freely with both transgenic TCR r  chains. The only 
possibility that our data do not preclude is that TCR com- 
plexes on double transgenic mice exclusively contain mul- 
tiple identical TCR or//3 pairs. Such a possibility would re- 
quire V-region incompatibilities not only between the two 
transgenic TCR cz proteins in different disulfide linked cx/3 
dimers, but also between the two transgenic TCR/3 pro- 
teins. It is difficult to imagine a physical basis for such a se- 
vere constraint. Thus, we conclude that each TCR complex 
contains only one TCR ot and one TCR/3 chain (Fig. 1 A). 
Quantitative surface  staining further demonstrates that 
CD3e and TCR/3 are expressed on the surface of normal 
T cells at a 2:1 ratio,  as proposed in Fig.  1 A. Because the 
anti-CD3e antibody 2Cll recognizes CD3e in association 
with either CD3"y or CD3~, there are two e containing dimers 
per TCP, complex (2~/e, 26e, or one of each), a stoichiom- 
etry previously advocated by the data and conclusions of de 
la Hera et al. (4). However, the precise stoichiometry of CD3& 
CD3%  and ~" proteins still remains unknown. We cannot 
reconcile our data with studies suggesting that CD3e and 
TCR/3 are present on the surface of T  cells in a 1:1 ratio 
(21, 22), since our immunofluorescent assessment clearly in- 
dicates that TCR B and CD3e proteins are present in a 1:2 
ratio.  Therefore, the present study demonstrates that there 
are precisely one TCR or, one TCR/3 and two CD3e pro- 
teins in a single TCK/CD3 complex. 
What made it possible for us to assess associations between 
the two different TCK c~ and the two different TCR/3 chains 
in double transgenic mice were the distinctive patterns each 
transgenic protein generated after they were stripped of their 
N-linked oligosaccharides before NEPHGE analysis. Without 
Endo F/PNGase digestion, the TCK proteins were indistin- 
guishable, although u-YV,,3 was slightly more acidic than 
^NDV,dl (data not shown). Every transgenic TCR protein 
except  "-vV~3  resolved  into several spots after  digestion. 
These biochemical signatures were remarkably reproducible 
and multiple additions of fresh Endo F/PNGase did not change 
the pattern of spots generated. The multiple spots formed 
by each TCR oe and TCR/3 chain during NEPHGE analysis 
presumably represent the variety of TCR protein products 
generated when mixed Endo F/PNGase activities  act upon 
a pool of heterogeneously  glycosylated TCK cx and/3 chains. 
It could also be a reflection of heterogeneity in accessibility 
of individual chains  to Endo F/PNGase digestion. 
The possibility that there were more than one TCR cx//3 
heterodimer per complex was originally raised to account for 
a number of observations, the most compelling of which was 
the recognition that an c~/fl/e ratio of 1:1:2 would result in 
a transmembrane charge imbalance (5). Because TCR c~ and 
TCK/3 chains have three positively charged transmembrane 
residues between them and the CD3 proteins and ~" chains 
each have one negatively charged transmembrane residue, a 
TCR/CD3 complex with one TCR ~//3, two CD3es, one ~" dimer, one CD3fi, and one CD37 would have a net charge 
of -3. It is possible that as yet unidentified proteins and/or 
lipids associate with the complex to maintain  charge neu- 
trality. A charge imbalance may, in fact, give the TCR/CD3 
complex the flexibility to interact with different surface pro- 
teins at different times during activation or differentiation. 
Alternatively, arithmetric calculations of net charge may not 
take into account complexities introduced by tertiary struc- 
ture which may mute the imbalance. It is also possible that 
charge neutrality is not critical for stability of surface pro- 
teins.  Indeed, the neu oncogene product is stably expressed 
on the cell surface despite a net negative charge of - 1 within 
its  transmembrane  domain  (23). 
Our findings offer an explanation  also proposed by de la 
Hera et al. (4) for data demonstrating a difference in the de- 
velopmental  and functional effects of anti-CD3e  and anti- 
TCR B (24-27). Because there are two CD3e chains per com- 
plex, anti-CD3e is capable of aggregating multiple receptor 
complexes and generating intraceUular signals through mul- 
tivalent cross-linking of TCR/CD3 components. However, 
because there is only one TCR/~ chain per TCR complex 
anti-TCR ~  can induce no more than bivalent TCR cross- 
linking. The signals transduced by bivalent rather than mul- 
tivalent cross-linking may be quantitatively and qualitatively 
distinct. 
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